Related Experiment Video
Updated: Jul 8, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Statin use and the risk of Parkinson disease
Angelika D Wahner1, Jeff M Bronstein, Yvette M Bordelon
1Department of Epidemiology, UCLA School of Public Health, 650 Charles E. Young Drive, Los Angeles, CA 90095-1772, USA. awahner@ucla.edu
Objective:
To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).
Methods:
We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.
Results:
We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.
Conclusion:
Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Alterations in Muscle Tone lll